Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth

Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 28, 2026

Arcutis Appoints Rob Scott, MD to Board of Directors

Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer.

GlobeNewsWire • Oct 28, 2026

Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston.

GlobeNewsWire • Oct 27, 2026

Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026

Arcutis today announced that it will report its Q3 2026 financial results and provide a business update after the U.S. financial markets close on Nov 4.

GlobeNewsWire • Oct 21, 2026

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) stock traded higher Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $48 price forecast, citing strong Zoryve sales growth and expansion opportunities in dermatology.

Benzinga • Oct 15, 2026

2 Stocks That Could Soar in Q4

Viking Therapeutics is set to commence key trials for its obesity drug VK2735. Arcutis Biotherapeutics is expanding Zoryve into new indications and age groups.

The Motley Fool • Oct 12, 2026

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to

GlobeNewsWire • Oct 9, 2026

Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Newly created award category highlights innovation in prescription skin treatment ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.15% was presented with the 2026 “Best Prescription Skin Solution” Award by Marie Claire magazine.

GlobeNewsWire • Oct 6, 2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 62,500 restricted stock units (RSUs) of Arcutis common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Oct 2, 2026

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Sep 17, 2026